Oncolytics Biotech Secures New Patents for Pelareorep to Extend IP into Late 2040s
Oncolytics Biotech Inc. (ONCY) has secured new method-of-use patents for its key drug candidate, pelareorep, as an immunotherapy in several international markets. The company also anticipates the issuance of a corresponding U.S. patent in the near future. Shares of the biotech firm traded down 15.03% at 0.4733 USD following the disclosure.
The expanded patent suite aims to protect pelareorep well beyond its current manufacturing patent lifecycle, which presently extends through 2044. Oncolytics Biotech Inc. is advancing three pending patent families that encompass combination therapies and method-of-use claims, seeking to push intellectual property exclusivity into the late 2040s.
Looking ahead, the company plans to request Track One expedited examination for a pending U.S. application this quarter, aiming for potential approval within approximately 12 months. Additionally, Oncolytics Biotech Inc. is collaborating with an academic partner on a modified next-generation version of pelareorep, with plans to file for a new composition-of-matter patent.
Key points
- Oncolytics Biotech Inc. secured international method-of-use patents for pelareorep as an immunotherapy, with a U.S. patent issuance expected soon.
- The company aims to extend intellectual property protection into the late 2040s, beyond its existing manufacturing patents that last through 2044.
- A pending U.S. application will be converted to Track One examination this quarter to target issuance within roughly 12 months.
- Oncolytics Biotech Inc. is developing a modified next-generation pelareorep with an academic partner to seek a composition-of-matter patent.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What patents did Oncolytics Biotech Inc. secure for pelareorep?
Oncolytics Biotech Inc. secured new method-of-use patents covering pelareorep as an immunotherapy in multiple countries, with a U.S. patent expected to issue soon.
How long does Oncolytics Biotech Inc. aim to protect pelareorep?
The company aims to extend intellectual property protection into the late 2040s, going beyond its current manufacturing patents that run through 2044.
What is Oncolytics Biotech Inc.'s timeline for its Track One patent application?
Oncolytics Biotech Inc. plans to convert a pending U.S. application to Track One status this quarter, targeting a prioritized examination period of about 12 months.